Healthcare / Medical DevicesNasdaqCM
$11.48
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-19.2M · quality 41.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
14/100
F
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$399M
P/E
N/A
•EV/EBITDA
N/A
•ROE
2.4%
↑Gross Margin
86.2%
↑Debt/Equity
N/A
•Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2009–2025 · 16 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
24.6%
FCF / Net income
7.77x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $85.2M · net income $2.7M · FCF $21.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||
| Revenue | $85.2M | $85.2M | $37.2M | $2.1M | $2.7M | $3.6M | — | — | — | — | — | $1.7M | $1.1M | $790000.00 | $346000.00 | $0.00 | $0.00 | — |
| Net Income | $2.7M | $2.7M | $-26.4M | $-47.7M | $-36.5M | $-25.6M | $-24.2M | $-8.9M | $-19.2M | $-45.1M | $-18.0M | $-14.7M | $-17.4M | $-30.3M | $-51.9M | $-30.9M | $-46.7M | $-22.1M |
| EPS | 0.07 | 0.07 | -0.93 | -2.94 | -4.12 | -3.59 | -8.35 | -342.83 | -0.72 | -3250.00 | — | -0.91 | -1.84 | -5.10 | -13.54 | -0.68 | — | — |
| Gross Margin | 86.2% | 86.2% | 83.4% | 69.2% | 74.8% | 81.1% | — | — | — | — | — | 73.6% | 72.8% | 41.3% | 88.7% | — | — | — |
| Operating Margin | 0.8% | 0.8% | -33.4% | -1849.0% | -1245.1% | -690.0% | — | — | — | — | — | -870.6% | -1805.8% | -4179.6% | -15569.7% | — | — | — |
| Net Margin | 3.2% | 3.2% | -70.9% | -2308.9% | -1342.7% | -721.5% | — | — | — | — | — | -841.7% | -1625.9% | -3838.5% | -14990.8% | — | — | — |
| Balance Sheet | ||||||||||||||||||
| Debt/Equity | — | — | 0.00 | 0.64 | -2.68 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||||
| Free Cash Flow | $21.0M | $21.0M | $-19.2M | $-31.3M | $-25.2M | $-22.7M | $-23.6M | $-23.7M | $-14.8M | $-15.9M | — | — | — | $-34.2M | $-52.1M | $-40.0M | $-25.7M | $-11.0M |
| Returns | ||||||||||||||||||
| ROE | 2.4% | 2.4% | -38.4% | -302.2% | 623.1% | -214.6% | -109.4% | 139.7% | 128.7% | -6654.4% | 1206.1% | -171.0% | -95.8% | -100.7% | -259.2% | -118.3% | -160.5% | -92.8% |
| Growth & Yield | ||||||||||||||||||
| Revenue Growth | 129.1% | 129.1% | 1701.7% | -24.1% | -23.5% | — | — | — | — | — | — | 63.4% | 35.3% | 128.3% | — | — | — | — |
| EPS Growth | 107.5% | 107.5% | 68.4% | 28.6% | -14.8% | 57.0% | 97.6% | -47515.3% | 100.0% | — | — | 50.5% | 63.9% | 62.3% | -1891.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
144.1%
EPS terminal req.
$1.02
Spread vs growth
-36.6%
5Y implied EPS CAGR
77.5%
EPS terminal req.
$1.23
Spread vs growth
30.0%
10Y implied EPS CAGR
39.7%
EPS terminal req.
$1.99
Spread vs growth
67.8%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Unavailable: positive start/end prices are required.